Ranbaxy Takes On Pfizer Over Lipitor

In an in-depth characteristic published today, Law.com reports on Indian generic pharma companionship Ranbaxy's assail on Pfizer's Lipitor (apparently the world's most prescribed drug). Pfizer is resisting the challenge to its patent together with it volition last about fourth dimension earlier the number of this dispute is known.

Lipitor: expert for lowering cholesterol levels; non then expert for lowering the blood pressure level of patent litigants

Curiously, the IPKat says, the writer of the article describes Ranbaxy equally the David to Pfizer's Goliath. This rather creates the impression that Ranbaxy, which makes its coin past times making together with selling inexpensive versions of drugs that accept been expensively together with carefully tested past times proprietary pharma companies, is about assort of small, weak outfit. Ranbaxy is nonetheless null of the sort. By the admission of its CEO, Brian Tempest,

"From a small-scale domestic companionship at inception, nosotros accept grown formidably to last a Billion dollar institution".

The company, which experienced 27% increment inwards the twelvemonth ending Dec 2003, at ane time employs 9,000 people. expects that it tin afford to tackle Pfizer inwards patent litigation without having to give-up the ghost circular the begging bowl.

Facts most cholesterol here and here
How cholesterol plant here
Cholesterol joke here